Zomedica Pharmaceuticals Corp is a veterinary-focused healthcare company dedicated to developing innovative diagnostic and therapeutic products for companion animals, particularly dogs and cats
The company aims to enhance the quality of care for pets and improve their health outcomes through its advanced diagnostic tools. Zomedica's flagship product line includes diagnostics that help veterinarians detect and monitor various health conditions, empowering them to make informed decisions regarding treatment options. With a commitment to improving animal health, Zomedica seeks to support veterinary practices with effective solutions that ultimately lead to better pet care.
Zomedica Corp (AMEX: ZOM) launches 2 new canine assays for its TRUFORMA platform. NT-proBNP test detects heart failure, progesterone test helps with breeding timing.
Zomedica (NYSEZOM) is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Their gold standard PulseVet(r) shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Their suite of products also includes the Assisi(r) Loop line of therapeutic devices and the TRUFORMA(r) diagnostic platform, the TRUVIEW(tm) digital cytology system, and the VetGuardian(r) no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. An NYSE American company, Zomedica grew revenue 33% in 2023 to $25 million and maintains a strong balance sheet with approximately $78 million in liquidity as of September 30, 2024. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as they work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information, visit the company’s website at: http://www.zomedica.com/
ANN ARBOR, MI / ACCESSWIRE / November 27, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that its Chief Executive Officer, Larry Heaton, will present and host one-on-one meetings with investors at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, Florida on Wednesday, December 4, 2025 at 11:00 am Eastern Standard Time.
Zomedica (NYSEZOM) is at the forefront of veterinary medicine, specializing in diagnostic solutions and therapeutics for pets. The company will be presenting alongside world-class headliners such as Zack Kass, former Head of Go-To-Market at OpenAI where ChatGPT was created, and “Shark Tank” stars Kevin O’Leary, Robert Herjavec, and Daymond John.
ANN ARBOR, MI / ACCESSWIRE / November 12, 2024 / Zomedica Corp. (NYSE American:ZOM), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, is pleased to announce that Noble Capital Markets has initiated company-sponsored equity research coverage on the Company. The full report by Noble Capital Markets Research Analyst Robert LeBoyer, as well as news and advanced market data on Zomedica Corp., is available on Channelchek.
ANN ARBOR, MI / ACCESSWIRE / November 8, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that Larry Heaton, Chief Executive Officer, will present and host one-on-one meetings with investors at the Sidoti Micro Cap Conference, taking place on November 13-14, 2024.
ANN ARBOR, MI / ACCESSWIRE / November 7, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the third quarter ended September 30, 2024.
ANN ARBOR, MI / ACCESSWIRE / October 23, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only webcast on Thursday, November 7, 2024, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its thirdquarter ended September 30, 2024. A question-and-answer session will follow management's prepared remarks.
Zomedica Corp. expands into Costa Rica with SIRE Veterinario as exclusive distributor. Strategic partnership aims to bring advanced veterinary solutions to local veterinarians.
